CONTROLLED RELEASE FORMULATIONS OF OCTREOTIDE
First Claim
Patent Images
1. A method of treating a patient suffering from a condition associated with carcinoid tumors or suffering from one or more symptoms associated with such condition, said method comprising:
- implanting subcutaneously into a patient in need thereof at least one implant comprising a hydrogel and a pharmaceutical formulation comprising octreotide;
wherein said pharmaceutical formulation is contained within said hydrogel, which hydrogel comprises a copolymer obtained from the copolymerization of a mixture comprising at least two hydrophilic, ethylenically unsaturated monomers;
wherein said pharmaceutical formulation contains between about 20 to about 150 milligrams of octreotide, in free form or salt form;
wherein said pharmaceutical formulation further comprises an effective amount of hydroxypropylcellulose; and
wherein said at least one implant releases a therapeutically effective amount of said octreotide to said patient over a period of at least about two months.
12 Assignments
0 Petitions
Accused Products
Abstract
A formulation of octreotide or pharmaceutically acceptable salts thereof, which provides controlled release of a therapeutically effective amount of octreotide for a period of at least about two months. Methods of treating acromegaly, decreasing growth hormone, decreasing IGF-1, and treating conditions associated with carcinoid tumors and VIPomas by administering a controlled release formulation of octreotide are provided herein.
82 Citations
25 Claims
-
1. A method of treating a patient suffering from a condition associated with carcinoid tumors or suffering from one or more symptoms associated with such condition, said method comprising:
-
implanting subcutaneously into a patient in need thereof at least one implant comprising a hydrogel and a pharmaceutical formulation comprising octreotide; wherein said pharmaceutical formulation is contained within said hydrogel, which hydrogel comprises a copolymer obtained from the copolymerization of a mixture comprising at least two hydrophilic, ethylenically unsaturated monomers; wherein said pharmaceutical formulation contains between about 20 to about 150 milligrams of octreotide, in free form or salt form; wherein said pharmaceutical formulation further comprises an effective amount of hydroxypropylcellulose; and wherein said at least one implant releases a therapeutically effective amount of said octreotide to said patient over a period of at least about two months. - View Dependent Claims (2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19)
-
-
20. A method of treating a patient suffering from a condition associated with overproduction of growth hormone or IGF-1 or suffering from one or more symptoms associated with such condition, said method comprising:
-
implanting subcutaneously into a patient in need thereof at least one implant comprising a hydrogel and a pharmaceutical formulation comprising octreotide; wherein said pharmaceutical formulation is contained within said hydrogel, which hydrogel comprises a copolymer obtained from the copolymerization of a mixture comprising at least two hydrophilic, ethylenically unsaturated monomers; wherein said pharmaceutical formulation contains between about 20 to about 150 milligrams of octreotide, in free form or salt form; wherein said pharmaceutical formulation further comprises an effective amount of hydroxypropylcellulose; and wherein said at least one implant releases a therapeutically effective amount of said octreotide to said patient over a period of at least about two months. - View Dependent Claims (21, 22)
-
-
23. A method of treating a patient suffering from a condition associated with VIP-secreting tumors or suffering from one or more symptoms associated with such condition, said method comprising:
-
implanting subcutaneously into a patient in need thereof at least one implant comprising a hydrogel and a pharmaceutical formulation comprising octreotide; wherein said pharmaceutical formulation is contained within said hydrogel, which hydrogel comprises a copolymer obtained from the copolymerization of a mixture comprising at least two hydrophilic, ethylenically unsaturated monomers; wherein said pharmaceutical formulation contains between about 20 to about 150 milligrams of octreotide, in free form or salt form; wherein said pharmaceutical formulation further comprises an effective amount of hydroxypropylcellulose; and wherein said at least one implant releases a therapeutically effective amount of said octreotide to said patient over a period of at least about two months. - View Dependent Claims (24, 25)
-
Specification